SI

Sapience Therapeutics, Inc.

www.sapiencetherapeutics.com link_icon

Company Research Report: Sapience Therapeutics, Inc.






Company Overview



Name, Mission of the Company


Sapience Therapeutics, Inc.
Sapience Therapeutics is committed to pioneering a new class of peptide-based cancer therapeutics, specifically targeting transcription factors known to drive oncogenesis and immune suppression in patients with high mortality cancers.

When was the Company Founded and by Whom


No information is available

Key People in the Company


  • Barry Kappel, Ph.D., M.B.A. - President, CEO and Founder

  • Marisa Frackman - Chief Financial Officer

  • Abi Vainstein-Haras, M.D. - Chief Medical Officer

  • Seth I. Rubin, J.D. - General Counsel

  • Nancy Dong, MPPM, CMA, SPHR - Chief Administrative Officer and Controller

  • Gene Merutka, Ph.D. - SVP, CMC and Operations

  • Jim Rotolo, Ph.D. - SVP, Research & Translational Sciences

  • Gina Capiaux, Ph.D. - VP, Regulatory Affairs


Where is the Company Headquartered


520 White Plains Road, Second Floor, Tarrytown, NY 10591

Number of Employees


No information is available

Revenue of the Company


No information is available

What is the Company Known For


Sapience Therapeutics is known for developing first-in-class peptide antagonists against elusive oncogenic and immune-modulating drug targets.




Products



What Products Do They Offer


Sapience Therapeutics specializes in a pipeline of peptide therapeutics, notably SPEARs™ (Stabilized Peptides Engineered Against Regulation).

1. ST101
2. ST316
3. JunAP (cJun Program)
4. FoxAP (FOXP3 Program)

High-Level Description of the Product



  • ST101

  • Description: First-in-class C/EBPβ antagonist with dual mechanisms of action inducing both tumor cell death and macrophage repolarization.

  • Key Features: Targets transcription factor C/EBPβ; promotes immune-activating functions and cytotoxicity.


  • ST316

  • Description: First-in-class β-catenin antagonist preventing β-catenin's nuclear translocation.

  • Key Features: Modulates Wnt signaling pathways; averts tumor cell proliferation and immunosuppression.


  • JunAP

  • Description: cJun targeted SPEAR inhibiting cJun and cFos interaction to disrupt AP-1 complex formation.

  • Key Features: Targets AP-1 transcription complex prevalent in various tumors; being optimized for clinical use.


  • FoxAP

  • Description: FOXP3 antagonist disrupting FoxP3 homodimers, thereby diminishing regulatory T cell development and function.

  • Key Features: Promotes anti-tumor immune responses by inhibiting FOXP3 transcription factor.


---

Recent Developments



What are the Recent Developments in the Company



  • 2024 Developments

  • June 1: Presented Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024.

  • May 23: Showcased Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024.

  • April 24: Announced Oral Presentation at 2024 ASCO Annual Meeting featuring ST101 Phase 2 results in GBM.

  • April 8: Presented Three Posters at AACR Annual Meeting 2024.

  • April 3: Presented at 23rd Annual Needham Virtual Healthcare Conference.

  • February 13: Presented at 2024 BIO CEO & Investor Conference.


  • 2023 Developments

  • November 17: Presented New ST101 Phase 2 Clinical Data in GBM at SNO Annual Meeting.

  • November 1: Announced Poster Presentation for ST101 in GBM at SNO Annual Meeting.

  • October 13: Presented ST101 Clinical Data and ST316 Preclinical Data at the AACR-NCI-EORTC International Conference.

  • June 13: Announced First Patient Dosed in Phase 1-2 Clinical Study of ST316.

  • May 4: Awarded $2 Million Grant for ST316 evaluation.


What are the New Products Launched


No information is available

What are the New Features Added to the Existing Products


  • ST101: Clinical and biomarker data continue to support its efficacy in Phase 2 studies.

  • ST316: Preclinical and Phase 1 data suggest anti-tumor immune responses through multiple mechanisms.


Any New Partnerships


No information is available




Conclusion



The above information highlights Sapience Therapeutics’ commitment to innovative peptide-based cancer therapeutics, detailing their key products, leadership, developments, and their ongoing clinical trials.

Contact information:
520 White Plains Road, Second Floor, Tarrytown, NY 10591
Tel: (914) 418-5100
All Rights Reserved © 2024 Sapience Therapeutics, Inc.